MEL-212: A Phase I Proof-of-Concept Study of CBL0137 (Curaxin) Combined With Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab.
研究概览
简要总结
Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.
详细描述
The primary objectives will be Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Pathologically proven stage III melanoma with one or more macroscopic lymph node metastases (measurable according to RECIST v. 1.1) amenable to biopsy and/or surgery OR:
- •Patients considered to have stage III or stage IV disease amenable to serial biopsies as determined by the treating physician. Note: patients with in-transit metastasis may be eligible after surgical consultation if not surgical candidates.
- •Patients must have disease amenable to and must be willing to undergo protocol-directed repeat biopsies and blood draws.
- •Age > 18 years
- •ECOG performance status 0 or 1
- •Patients must have normal organ and marrow function
排除标准
- •Patients may not be receiving any other investigational agents
- •Patients with a known active autoimmune disease
- •Prior treatment with CTLA-4 or PD1/PD-L1 pathway targeted systemic treatment
- •Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids
- •Patients with ongoing diarrhea (> 4 bowel movements/day) unresolved despite medical and best supportive care in the two weeks preceding therapy
研究组 & 干预措施
CBL0137 (Dose level 1) +Ipilimumab + Nivolumab
Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: Ipilimumab (Drug)
CBL0137 (Dose level 1) +Ipilimumab + Nivolumab
Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: Nivolumab (Drug)
CBL0137 ( Dose level 2) +Ipilimumab + Nivolumab
Dose level 2 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: Ipilimumab (Drug)
CBL0137 ( Dose level -1) +Ipilimumab + Nivolumab
Dose level -1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: CBL0137 (Drug)
CBL0137 (Dose level 1) +Ipilimumab + Nivolumab
Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: CBL0137 (Drug)
CBL0137 ( Dose level 2) +Ipilimumab + Nivolumab
Dose level 2 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: CBL0137 (Drug)
CBL0137 ( Dose level 2) +Ipilimumab + Nivolumab
Dose level 2 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: Nivolumab (Drug)
CBL0137 ( Dose level -1) +Ipilimumab + Nivolumab
Dose level -1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: Ipilimumab (Drug)
CBL0137 ( Dose level -1) +Ipilimumab + Nivolumab
Dose level -1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
干预措施: Nivolumab (Drug)
结局指标
主要结局
Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab.
时间窗: 28 days
The primary endpoint will be safety/tolerability of the combination of CBL0137 with ipilimumab and nivolumab. Patients will be treated as part of assigned dose level in planned 3+ 3 design with 3 possible dose levels and assessed for Dose limiting toxicities ( DLTs)
次要结局
未报告次要终点